Equities research analysts at StockNews.com started coverage on shares of Amarin (NASDAQ:AMRN - Get Free Report) in a research note issued to investors on Friday. The firm set a "hold" rating on the biopharmaceutical company's stock.
Amarin Stock Performance
Shares of Amarin stock traded down $0.01 on Friday, hitting $0.46. 2,519,218 shares of the company's stock were exchanged, compared to its average volume of 1,553,071. Amarin has a 1 year low of $0.43 and a 1 year high of $1.37. The company has a 50-day simple moving average of $0.54 and a 200-day simple moving average of $0.62. The stock has a market capitalization of $188.91 million, a PE ratio of -5.11 and a beta of 1.83.
Amarin (NASDAQ:AMRN - Get Free Report) last posted its quarterly earnings results on Wednesday, October 30th. The biopharmaceutical company reported ($0.06) EPS for the quarter, missing analysts' consensus estimates of ($0.04) by ($0.02). The business had revenue of $42.30 million during the quarter, compared to analysts' expectations of $43.82 million. Amarin had a negative return on equity of 7.22% and a negative net margin of 16.33%. During the same period in the prior year, the firm posted ($0.05) earnings per share. On average, analysts expect that Amarin will post -0.14 EPS for the current fiscal year.
Hedge Funds Weigh In On Amarin
A number of institutional investors and hedge funds have recently modified their holdings of the stock. China Universal Asset Management Co. Ltd. grew its position in Amarin by 63.9% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 76,959 shares of the biopharmaceutical company's stock valued at $48,000 after acquiring an additional 29,992 shares during the last quarter. Kornitzer Capital Management Inc. KS raised its position in Amarin by 80.7% during the 3rd quarter. Kornitzer Capital Management Inc. KS now owns 95,600 shares of the biopharmaceutical company's stock valued at $60,000 after purchasing an additional 42,700 shares in the last quarter. Algert Global LLC purchased a new stake in shares of Amarin in the 2nd quarter worth $34,000. BNP Paribas Financial Markets grew its position in shares of Amarin by 8.8% during the 3rd quarter. BNP Paribas Financial Markets now owns 1,301,468 shares of the biopharmaceutical company's stock worth $816,000 after buying an additional 104,939 shares in the last quarter. Finally, Waterfront Wealth Inc. increased its stake in shares of Amarin by 63.7% during the second quarter. Waterfront Wealth Inc. now owns 860,613 shares of the biopharmaceutical company's stock valued at $592,000 after buying an additional 334,969 shares during the period. Hedge funds and other institutional investors own 22.25% of the company's stock.
Amarin Company Profile
(
Get Free Report)
Amarin Corporation plc, a pharmaceutical company, engages in the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States, European countries, Canada, Lebanon, and the United Arab Emirates. The company offers VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia.
Featured Stories
Before you consider Amarin, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Amarin wasn't on the list.
While Amarin currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
